Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Siegfried is acquiring a manufacturing facility in Grafton, WI, from the CDMO Curia Global, adding to its current network of 12 sites. Siegfried will also gain over 80 staffers working at the Grafton site. The transaction is expected to close in July. Siegfried said Wednesday that the facility will provide services in early-phase manufacturing including high-potency active pharmaceutical ingredients.
Merck KGaA is pouring €62 million ($67 million) into its Darmstadt headquarters in Germany for a new quality control building. The new facility will hire around 135 employees. The building will be finished by mid-2025, according to a June 6 release.
NorthStar Medical Radioisotopes and Monopar Therapeutics are updating their existing partnership, which saw Northstar supply the isotope actinium-225 to Monopar for its lead solid cancer candidate, dubbed MNPR-101. Under the updated partnership, Monopar will gain complete ownership of MNPR-101 and NorthStar will supply Ac-225 for future investigations, according to a Tuesday release.
AGC Biologics is manufacturing Essential Pharma’s monoclonal antibody for high-risk neuroblastoma, the companies announced Tuesday.
Dec Group is acquiring the German arm of Bausch, which specializes in aseptic fill-finish packaging. Bausch Germany will become a subsidiary of Dec, according to a Wednesday release.
UPS Healthcare is expanding its European hub in Roermond, the Netherlands, which will add space for over 200 ultra-low temperature freezers that can store products at -80°C, the company told Endpoints News.
Private equity firm Thompson Street Capital Partners is merging two companies in its portfolio: Vector Laboratories and Absolute Biotech. Vector manufactures reagents and components of life science tools, diagnostic products and clinical-stage therapies. Absolute Biotech is an antibody manufacturer. Lisa Sellers, CEO of Vector, will run the merged company, a Tuesday release said.
Alvotech and STADA are extending their existing partnership to include STADA’s investigational biosimilar AVT03. The candidate is being studied as a biosimilar for denosumab, which is approved to help decrease bone resorption and cancer-related bone damage. Alvotech will manufacture the asset at its site in Reykjavik, Iceland, according to a Monday release.